human immunoglobulin (pH4) for intravenous injection / Peking Union Medical College - LARVOL DELTA

PERSISTENT HYPONATREMIA AS A DISTINCTIVE FEATURE OF HHV-6B ENCEPHALITIS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A CASE SERIES (EBMT 2026) - "All five patients were administered antiviral therapy comprising ganciclovir, foscarnet, and intravenous immunoglobulin. Persistent hyponatremia during engraftment after HSCT or CRS post-CAR-T therapy could indicate HHV-6B encephalitis in children, highlighting the need for CNS evaluation for diagnosis."

Clinical • IO biomarker • Bone Marrow Transplantation • Cardiovascular • CNS Disorders • Dermatology • Endocrine Disorders • Epilepsy • Heart Failure • Inflammation • Juvenile Myelomonocytic Leukemia • Movement Disorders • Nephrology • Pediatrics • Pruritus • Rare Diseases • T Acute Lymphoblastic Leukemia • Transplantation • CD7

Fetal echocardiographic surveillance in anti-SSA/Ro-SSB/La-Positive systemic lupus erythematosus pregnancies: risk stratification of congenital heart block. (PubMed, Rheumatology (Oxford)) - "SLE pregnancies with anti-SSA/Ro-SSB/La antibodies and suboptimal gestational conditions constitute a distinct high-risk subgroup. A management strategy through risk-stratified serial fetal AVI monitoring allows for precise treatment identification, significantly improving neonatal outcomes while avoiding unnecessary interventions."

Journal • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Fulminant disseminated human parvovirus B19 infection: Case report. (PubMed, IDCases) - "Despite negative B19-specific IgM, the patient improved after four weeks of supportive care and two courses of intravenous immunoglobulin, with recovery of renal, hepatic, and respiratory function and resolution of rectal lesions. Disseminated HPV B19 infection should be considered in unexplained multiorgan dysfunction, even in the absence of rash or IgM seroconversion. Early PCR-based testing of blood and affected tissues can be diagnostic."

Journal • Colorectal Cancer • Critical care • Hematological Disorders • Hepatology • Infectious Disease • Liver Failure • Nephrology • Thrombocytopenia

Single-cell transcriptomic analysis reveals a systemic immune dysregulation in intravenous immunoglobulin non-responsive Kawasaki disease. (PubMed, Front Immunol) - "The expression levels of S100A8/A9, S100A12, TNF, TNFSF8/10, and interferon-α were consistent with the transcriptomic data. Our findings reveal the immune landscape in IVIG non-responsive KD and suggest potential targets for alternative therapies."

Journal • Inflammation • MYD88 • S100A12 • S100A8 • TLR4 • TNFSF8

Persistent hyponatremia as a distinctive feature of HHV-6B encephalitis in pediatric hematopoietic stem cell transplant recipients: A case series (ASH 2025) - "All five patients were administered antiviral therapy comprising ganciclovir, foscarnet, and intravenous immunoglobulin. Persistent hyponatremia may act as a distinctive clinical indicator of HHV-6B encephalitis in pediatric patients undergoing HSCT. The underlying mechanisms require further investigation."

Clinical • IO biomarker • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Cardiovascular • Chronic Myelomonocytic Leukemia • CNS Disorders • Dermatology • Endocrine Disorders • Epilepsy • Heart Failure • Hematological Malignancies • Infectious Disease • Juvenile Myelomonocytic Leukemia • Leukemia • Movement Disorders • Myelodysplastic Syndrome • Nephrology • Pediatrics • Pruritus • Rare Diseases • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • Transplantation • CD7

Trial in progress: Study design of a randomized, phase 3 trial evaluating the efficacy and safety of mezagitamab (TAK-079) compared with placebo in adults with chronic primary immune thrombocytopenia (ASH 2025) - P2, P3 | "Use of additional, stable Background ITPtherapy is permitted, including corticosteroids, thrombopoietin receptor agonists, and fostamatinib, as isuse of rescue therapy (corticosteroids, intravenous immunoglobulin, platelet transfusion) whenindicated. Given promising, early-stage results for anti-CD38 treatment in patients who have beendifficult to manage on current therapies, this global study will evaluate the efficacy and safety ofsubcutaneous mezagitamab as a potential novel therapy for patients with ITP who have had aninsufficient response or intolerance to prior therapy."

Clinical • P3 data • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

Real-world safety and effectiveness of hetrombopag in patients with primary immune thrombocytopenia (ASH 2025) - P | "Management of ITP remains challenging, particularly forpatients who are refractory or intolerant to first-line treatments such as corticosteroids or intravenousimmunoglobulin (IVIg). Hetrombopag demonstrated favorable real-world safety and effectiveness in patients withITP, leading to sustained improvements in platelet counts and reduced reliance on concomitanttherapies. These findings provide meaningful evidence supporting the use of hetrombopag in routineclinical practice and underscore its potential as a core component in the long-term management of ITP."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA) (ASH 2023) - P2, P3 | "Ianalumab is a novel, fully human immunoglobulin G1 monoclonal antibody that targets BAFF receptor (BAFF-R) and has a unique dual mechanism of action: direct antibody-dependent cellular cytotoxicity-mediated B-cell depletion and inhibition of B-cell differentiation, proliferation and survival via blockade of BAFF-R-mediated signaling...Thrombopoietin receptor agonists (TPO-RAs), such as eltrombopag, are commonly used second-line ITP treatments and often achieve a response; however, responses are rarely maintained once treatment ends, so chronic administration is typically required. For wAIHA, few treatments have been approved, and patients rarely achieve durable responses on CS or off-label rituximab... These trials have been designed based on the hypothesis that, when administered early in disease progression, medical therapy targeting complementary physiological pathways may restore self-tolerance in patients with ITP and wAIHA. Ianalumab in combination with..."

Clinical • P3 data • Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

Epidemiologic trends of Kawasaki Disease and the potential impact of COVID-19 pandemic in Shanghai from 2018 through 2022. (PubMed, Chin Med J (Engl)) - "The incidence of KD in Shanghai showed a downward trend during 2018-2022 compared to 2013-2017. The containment measures implemented during the COVID-19 pandemic, such as citywide suspension of work and school closures, may have affected the incidence of KD."

Journal • Cardiovascular • Infectious Disease • Novel Coronavirus Disease • Pediatrics

Short-Term Efficacy of Combination Therapy with Recombinant Human Thrombopoietin (rh-TPO) and Thrombopoietin Receptor Agonists (TPO-Ra) in Patients with Severe Immune Thrombocytopenia (ASH 2023) - "When the risk of bleeding is becoming high or life-threatening bleeding events occurs, we often use a combination of therapies to rapidly raise platelets to the safe range, including platelet transfusions, high-dose glucocorticoid, and intravenous immunoglobulins...The patients were divided into three groups according to the medication used: rh-TPO group(rh-TPO 30000IU Qd), TPO-Ra group(Eltrombopag 25mg-75mg/d or Avatrombopag 2...5mg/d or Hetrombopagolamine 20mg-60mg/d), and rh-TPO+TPO-Ra group(combination of two drugs at the same dosage)...Further details are provided in Table 2. ConclusionThis retrospective study suggests that the patients with severe ITP who were refractory to glucocorticoids, the use of rh-TPO and TPO-Ra may rapidly increase to safe ranges, but the combination is not necessary."

Clinical • Combination therapy • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Identification of Metabolic Biomarkers Associated with the Efficacy of Intravenous Immunoglobulin in the Treatment of Immune Thrombocytopenia Based on Machine Learning (ASH 2024) - "Enrichment factors and P-values revealed the top metabolically enriched pathways to be purine metabolism, arginine biosynthesis, the mTOR signaling pathway, ether lipid metabolism. In summary, this study revealed the metabolic pathways in plasma associated with differences in IVIG efficacy and identified potential metabolic biomarkers distinguishing IVIG response."

Biomarker • Clinical • Machine learning • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Metabolic Disorders • Thrombocytopenia • Thrombocytopenic Purpura

An clinical trial of intravenous human immunoglobulin for the treatment of multifocal motor neuropathy (ChiCTR) - P4 | N=6 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital; Peking Union Medical College Hospital

New P4 trial • Complement-mediated Rare Disorders • Pain

`Integrated multi-modal dissection of IVIg-mediated immune reprogramming in lupus mice. (PubMed, Life Sci) - "Intravenous immunoglobulin (IVIg) is widely used to treat autoimmune diseases, yet its precise mechanisms of action in systemic lupus erythematosus remain incompletely understood...At the immune-cell level, IVIg was associated with alterations in T and B cell activation states, partial restoration of immune repertoire diversity, and shifts in dendritic cell populations. Collectively, our integrated analyses suggest that IVIg treatment is correlated with broad immunomodulatory changes in splenic immune composition in lupus-prone mice."

Journal • Preclinical • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Renal Disease • Systemic Lupus Erythematosus

Guidelines for the diagnosis and management of childhood immunoglobulin A vasculitis. (PubMed, World J Pediatr) - "This guideline provides evidence-based recommendations for the diagnosis and management of IgAV in children. This will facilitate improved and standardized care."

Journal • Review • Glomerulonephritis • Nephrology • Pediatrics • Renal Disease • Rheumatology • Vasculitis

Good syndrome presenting with multiple pulmonary infections: a case report involving metagenomic sequencing diagnosis. (PubMed, Front Med (Lausanne)) - "This patient received an intensified anti-infective regimen, with broad-spectrum carbapenem, meropenem, as the backbone therapy, combined with antifungal agents and antiviral treatment (IV ganciclovir and oral molnupiravir). After aggressive anti-infection therapy, the patient experienced clinical improvement, and chest CT demonstrated significant radiographic improvement. Although intravenous immunoglobulin (IVIG) is foundational in GS, intensive antimicrobial therapy is also critical for clinical outcomes."

Journal • Cough • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Herpes Simplex • Infectious Disease • Novel Coronavirus Disease • Primary Immunodeficiency • Respiratory Diseases • Solid Tumor • Thymoma • Thymus Cancer

Recurrent COVID-19 in a patient with Good's syndrome: a case report and literature review (PubMed, Zhonghua Nei Ke Za Zhi) - "Clinical symptoms improved following two courses of nirmatrelvir/ritonavir and four courses of molnupiravir, administered alongside adjunctive glucocorticoids and regular intravenous immunoglobulin (IVIG) supplementation. In the context of COVID-19, potential treatment strategies include extended multi-agent antiviral therapy guided by viral load, use of convalescent plasma (where available), and glucocorticoids tailored to disease severity. Further research is needed to define the optimal duration and combination of antiviral and immunomodulatory therapies in this population."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Solid Tumor • Thymoma • Thymus Cancer

NURSING CARE OF 7 CASES OF EPSTEIN-BARR VIRUS INFECTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION TREATED BY CYTOTOXIC T LYMPHOCYTES (EHA 2025) - " Routine immunization The reduction of conventional immunosuppressants, the first-line treatment of acyclovir and human immunoglobulin antiviral therapy, and rituximab showed no significant decrease in the copy number of EBV. Ebvemia /PTLD is a serious complication after hematopoietic stem cell transplantation with high mortality. Nurses should be familiar with the early clinical manifestations of this disease, including fever and local or systemic lymph node enlargement. To understand the risk factors of EBV-blood and EBV-PTLD after transplantation (grade Ⅲ/Ⅳ acute graft-versa-host disease, moderate and severe chronic graft-versa-host disease, cytomegaloviremia, etc.), to observe and care for the disease, and to master the CTL cell infusion method (ECG monitoring and promethazine before infusion; Observation and nursing of adverse reactions (fever, infection, TA-TMA, GVHD) were adopted to improve the cure rate of the disease."

Clinical • Bone Marrow Transplantation • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Oncology • Respiratory Diseases • Transplantation

COMPARATIVE ANALYSIS OF CD19 CAR T CELL MANUFACTURING AND PHARMACOKINETICS IN SLE AND B-ALL PATIENTS (EHA 2025) - P=N/A, P1/2 | "Before infusion, patients received fludarabine (30 mg/m2/day) and cyclophosphamide (250 mg/m2/day) on days -5, -4, and -3 to reach lymphodepletion.Between Oct 17th, 2024 and Jan 8th, 2025, 10 SLE patients received CD19 CAR T cell infusion...Total immunoglobulin levels were decreased despite the therapy with intravenous human immunoglobulin in 5 patients within one month... CAR T cell manufacturing efficiency was lower in SLE compared to B-ALL patients, potentially due to differences in intrinsic T-cell properties. SLE patients demonstrated inferior persistence of CD19 CAR T cells, which may affect the efficacy."

CAR T-Cell Therapy • Clinical • PK/PD data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Immunology • Inflammatory Arthritis • Leukemia • Lupus • Oncology • Systemic Lupus Erythematosus • CD19 • CD22 • CD8 • EGFR • IL6 • LAMP1

Case Report: Anti-ADAM23 antibody: an overlooked autoantibody against VGKC-complex in autoimmune encephalitis. (PubMed, Front Immunol) - "During the early stages of the disease, the patient underwent several courses of intravenous immunoglobulin (IVIg) with limited efficacy. Following the addition of high-dose methylprednisolone pulse therapy, the patient's consciousness improved from coma to stupor and the seizures were relieved. We propose that anti-ADAM23 antibody, a previously overlooked autoantibody targeting the VGKC complex, may have diagnostic significance for autoimmune encephalitis."

Journal • CNS Disorders • Epilepsy • Herpes Simplex • Immunology • Oncology

Efficacy and safety of a new 10% intravenous immunoglobulin (IVIG) in Chinese patients with primary immune thrombocytopenia (ITP): a multicenter, single-arm, phase III trial. (PubMed, Clin Exp Med) - "The therapeutic regimen of 10% IVIG administered at a dosage of 1 g/kg/day for two consecutive days demonstrated both favorable safety profiles and clinical efficacy. These robust findings provide substantial evidence supporting the clinical application of this novel 10% IVIG formulation in the management of adult patients with ITP."

Journal • P3 data • Hematological Disorders • Immune Thrombocytopenic Purpura • Pain • Thrombocytopenia • Thrombocytopenic Purpura

Efficacy and safety analysis of China's first 10% IVIg (RonsenGlob) therapy in treating adult ITP. (PubMed, Ann Hematol) - "A prospective, single-arm, open-label Phase III clinical trial was conducted across multiple centers in China from April 27, 2020, to June 15, 2021, to assess the efficacy and safety of 10% intravenous immunoglobulin (IVIg) in treating adult immune thrombocytopenic purpura (ITP)...Post-treatment bleeding scores significantly decreased, and no significant adverse reactions were reported. This inaugural study highlights the efficacy and safety of 10% IVIg in the urgent management of adult ITP, positioning it as a rapid therapeutic option."

Journal • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenic Purpura

A children patient with intracranial infection after brain surgery associated with elevated Torque Teno Virus. (PubMed, IDCases) - "NGS identified TTV in the CSF, prompting the addition of intravenous immunoglobulin...Prompt fungal testing including qPCR is recommended when TTV is detected in CSF. Further research is needed to elucidate the role of TTV in clinical infections and optimize management strategies."

Journal • Infectious Disease

Successfully salvaging a HIV-positive patient with mixed CIDP and meningoencephalitis: a case report. (PubMed, Front Med (Lausanne)) - "We describe an acquired immunodeficiency syndrome (AIDS) patient who first exhibited chronic inflammatory demyelinating polyneuropathy (CIDP) and subsequently developed meningoencephalitis due to ganciclovir (GCV)-resistant cytomegalovirus (CMV) infection...After the combined application of intravenous immunoglobulin treatment, corticosteroid treatment, antiretroviral therapy (ART), and adjusted anti-CMV treatment, the patient achieved persistent relief. This case underscores the importance of considering CMV as a common etiology of neurological disorders in AIDS patients. It also highlights the necessity of prompt drug resistance testing when anti-CMV therapy yields suboptimal responses."

Journal • CNS Disorders • Cytomegalovirus Infection • Human Immunodeficiency Virus • Infectious Disease • Pain

Antibody-positive paraneoplastic neurological syndromes associated with immune checkpoint inhibitors: a systematic review. (PubMed, J Neurol) - "Limbic encephalitis and anti-Hu antibody are relatively common in antibody-positive ICI-PNS, and most patients present with CSF inflammation. Discontinuation of ICIs and corticosteroids are the main treatments. High-risk antibodies may be a risk factor for an unfavorable prognosis, particularly anti-Hu and anti-Ma2 antibodies."

Checkpoint inhibition • Journal • Review • CNS Disorders • Lung Cancer • Melanoma • Merkel Cell Carcinoma • Myasthenia Gravis • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor

Autoimmune encephalitis associated with anti-LGI1 antibody: a potential cause of neuropsychiatric systemic lupus erythematosus. (PubMed, Lupus Sci Med) - "Screening for anti-LGI1 antibodies in patients with neuropsychiatric systemic lupus erythematosus (NPSLE) is crucial when limbic encephalitis presents, as it enables timely and effective treatment, potentially improving patients' outcomes. Additional basic and clinical research is required to clarify the pathogenic role of these antibodies in NPSLE."

Journal • Brain Cancer • CNS Disorders • CNS Tumor • Epilepsy • Glioma • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Mental Retardation • Oncology • Pneumonia • Psychiatry • Respiratory Diseases • Solid Tumor • Systemic Lupus Erythematosus